Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
NRSN | US
-0.03
-2.96%
Healthcare
Biotechnology
30/06/2024
09/03/2026
0.84
0.85
0.89
0.82
NeuroSense Therapeutics Ltd. a clinical-stage biotechnology company focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. Its lead product is PrimeC an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya Israel.
View LessLow Debt to Equity (< 0.25)
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
71.5%1 month
84.7%3 months
89.4%6 months
88.7%-
-
4.15
-0.02
0.02
-1.16
-
-
-11.69M
16.65M
16.65M
-
-
-
-
-494.84
1.04
1.83
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.11
Range1M
0.25
Range3M
0.42
Rel. volume
1.32
Price X volume
177.95K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Cue Biopharma Inc | CUE | Biotechnology | 0.301 | 18.12M | 0.40% | n/a | 52.09% |
| Enveric Biosciences Inc | ENVB | Biotechnology | 1.99 | 17.75M | 2.31% | n/a | 0.00% |
| Evaxion Biotech A/S | EVAX | Biotechnology | 3.08 | 17.18M | -4.35% | n/a | 837.11% |
| VistaGen Therapeutics Inc | VTGN | Biotechnology | 0.615 | 16.64M | 1.20% | n/a | 1.90% |
| GeoVax Labs Inc | GOVX | Biotechnology | 1.92 | 16.37M | 7.26% | n/a | -6.03% |
| Aytu BioScience Inc | AYTU | Biotechnology | 2.61 | 16.05M | 3.57% | n/a | 54.59% |
| Genenta Science S.p.A | GNTA | Biotechnology | 0.8574 | 15.62M | -0.31% | n/a | 0.00% |
| ImmunoCellular Therapeutics Ltd | IMUC | Biotechnology | 0.133 | 14.85M | 0.02 | -82.78% | |
| ADTX | ADTX | Biotechnology | 3.47 | 14.65M | 645.27% | n/a | 122.46% |
| Marker Therapeutics Inc | MRKR | Biotechnology | 1.47 | 13.12M | 6.52% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.6001 | 11.60M | -5.42% | n/a | 58.43% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 3.98 | 6.06M | -4.33% | n/a | 204.46% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.47 | 3.75M | -0.67% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.39 | 3.71M | -1.76% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.46 | 1.36M | 2.93% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.008 | 737.72K | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.16 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.15 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 89.40 | 72.80 | Riskier |
| Debt to Equity | -0.02 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 16.65M | 3.66B | Emerging |